Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A166 in Advanced HER2+ Solid Tumors
NCT03602079Phase 2Completed
- Sponsor
- KLUS Pharma
- Start
- Jul 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab botidotin in HER2-positive solid tumor, breast cancer and gastric cancer (GC) (5 arms), sponsored by KLUS Pharma. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Jul 2018; status: completed.
02
Drugs
trastuzumab botidotin
03
Conditions
HER2-positive solid tumorbreast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03602079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602079.